Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription elongation regulator 1 (TCERG1) is a nuclear protein that modulates transcriptional elongation and pre-mRNA splicing. It operates as a transcription factor interacting with the hyperphosphorylated C-terminal domain of RNA polymerase II via multiple FF domains, and with the pre-mRNA splicing factor SF1 via a WW domain. TCERG1 is involved in releasing RNA polymerase II from promoter-proximal pausing, thereby facilitating productive transcriptional elongation. It also plays a role in the alternative splicing of pre-mRNA and regulates the phosphorylation state of RNA polymerase II, specifically at serine 2 of its CTD. TCERG1 is necessary for TAT-dependent activation of the HIV-1 promoter and is required for efficient HIV-1 replication, making it a candidate therapeutic target in HIV-1 infection. Disease associations include roles in colorectal cancer and Huntington disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription elongation regulator 1 (TCERG1).